Published : 07 Jul 2026

---

CHICAGO, IL - July 07, 2026: Aagami is pleased to announce a new client win: we have been appointed by an innovative biopharmaceutical company based in Belgium. Under this exclusive mandate, Aagami will lead partner search and deal facilitation to identify, qualify, and secure premier commercialization and licensing partners in unassigned regions for the client’s breakthrough joint health solution.

 

The client has developed and gained CE-mark approval for a novel, once a year dose single-injection bioresorbable fluid implant indicated for the symptomatic management of Knee Osteoarthritis (OA). Unlike conventional therapies, this patented non-animal polymer technology provides durable lubrication, protects endogenous synovial components, and demonstrates clinically proven symptom relief even in advanced and difficult-to-treat OA patient segments.

 

Key Scope of Engagement

• Partner Identification: Mapping the orthopedic, rheumatology, and surgical specialty landscapes to identify, assess, and qualify strategic marketing and distribution partners.

 

• Licensing & Commercial Deal Structuring: Assisting with outreach, pitch presentations, technical dossiers, and valuation discussions to align commercialization incentives.

 

• Negotiation & Transaction Advisory: Providing strategic guidance and hands-on transaction support through partner due diligence and definitive agreement negotiations.

 

This engagement reinforces Aagami’s proven cross-border dealmaking capabilities in helping European life science and medical technology leaders capture high-growth opportunities across the healthcare market.